tumsasedgars / iStockphoto.com

8 June 2018Americas

BIO 2018: Allergan-tribe deal just the start, says former USPTO director

“The Saint Regis Mohawk Tribe issue is not unique to just life sciences—we’re likely to see it across the board. There’s likely been other transfers that are not yet public information,” said Teresa Rea, vice-chair of Crowell & Moring’s IP group and former director of the US Patent and Trademark Office (USPTO).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

8 June 2018 Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More features

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly

WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations

Boies Schiller Flexner adds three-strong litigation team

AstraZeneca forced to clarify deal terms in row with university

Novartis loses cancer drug patent following Teva challenge at EPO

A step too far? Why Stewart’s approach is dividing opinion

WATCH: Section 112—Where has the dust settled?